

1 **Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-**
2 **19 vaccination**

3
4 Hope R. Lapointe^{1*}, Francis Mwimanzi^{2*}, Peter K. Cheung^{1,2}, Yurou Sang², Fatima Yaseen³,
5 Rebecca Kalikawe², Sneha Datwani², Rachel Waterworth², Gisele Umviligihozo², Siobhan
6 Ennis², Landon Young⁴, Winnie Dong¹, Don Kirkby¹, Laura Burns⁵, Victor Leung^{4,5,6}, Daniel T.
7 Holmes^{5,6}, Mari L. DeMarco^{5,6}, Janet Simons^{5,6}, Nancy Matic^{4,5,6}, Julio S.G. Montaner^{1,7},
8 Chanson J. Brumme^{1,7}, Natalie Prystajeky^{6,8}, Masahiro Niikura², Christopher F. Lowe^{4,5,6}, Marc
9 G. Romney^{4,5,6#}, Mark A. Brockman^{1,2,3#}, Zabrina L. Brumme^{1,2#}

10
11 * and # denote equal contribution

12
13 1 British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada;

14 2 Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;

15 3 Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby,
16 Canada;

17 4 Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada;

18 5 Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver,
19 Canada;

20 6 Department of Pathology and Laboratory Medicine, University of British Columbia,
21 Vancouver, Canada

22 7 Department of Medicine, University of British Columbia, Vancouver, Canada;

23 8 British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, Canada

24
25
26 **Abstract:** 149 words

27 **Main Text:** 2984 words

28 **Enclosures:** 2 Figures; 1 Supplementary Figure

29
30 **Key words:** COVID-19, vaccine, Omicron variant, reinfection, humoral immunity

31
32 **Corresponding author:**

33 Zabrina L. Brumme, Ph.D.

34 Professor, Faculty of Health Sciences, Simon Fraser University

35 8888 University Drive, Burnaby, BC, Canada, V5A 1S6

36 Email: zbrumme@sfu.ca

37 **ABSTRACT**

38

39 SARS-CoV-2 Omicron infections are common among individuals who are vaccinated or have
40 recovered from prior variant infection, but few reports have documented serial Omicron
41 infections. We characterized SARS-CoV-2 humoral responses in a healthy young person who
42 acquired laboratory-confirmed Omicron BA.1.15 ten weeks after a third dose of BNT162b2, and
43 BA.2 thirteen weeks later. Responses were compared to those of 124 COVID-19 naive
44 vaccinees. One month after the second and third vaccine doses, the participant's wild-type and
45 BA.1-specific IgG, ACE2 competition and virus neutralization activities were average for a
46 COVID-19 naive triple-vaccinated individual. BA.1 infection boosted the participant's responses
47 to the cohort ≥ 95 th percentile, but even this strong "hybrid" immunity failed to protect against
48 BA.2. Moreover, reinfection increased BA.1 and BA.2-specific responses only modestly. Results
49 illustrate the risk of Omicron infection in fully vaccinated individuals and highlight the
50 importance of personal and public health measures as vaccine-induced immune responses wane.

51

52

53 INTRODUCTION

54

55 SARS-CoV-2 infections, predominantly fueled by the Omicron (B.1.1.529) variant, are
56 increasingly common among individuals who are vaccinated and/or have recovered from prior
57 infections (1-3). Globally, the highly transmissible and immune evasive Omicron variant has
58 rapidly overtaken the previously dominant Delta variant (3-7), and the original Omicron BA.1
59 strain is being outcompeted by newer Omicron sub-lineages BA.2, BA.3, BA.4 and BA.5 (8, 9).
60 In British Columbia (BC), Canada, Omicron BA.1 had overtaken Delta by December 2021 and
61 BA.2 had largely outcompeted BA.1 by March 2022 (10, 11).

62

63 COVID-19 vaccine coverage in BC is relatively high, with 93%, 90% and 57% of individuals
64 aged 12 years or older having received one, two and three COVID-19 immunizations,
65 respectively (12). Persons at elevated risk of severe COVID-19 are also eligible for fourth doses
66 (13). Despite this, the province experienced fifth and sixth waves of COVID-19, dominated by
67 BA.1 and BA.2, respectively, as public health measures were gradually relaxed (10, 11). Indeed,
68 it is estimated that between December 2021 and March 2022, nearly half of British Columbians
69 experienced a SARS-CoV-2 infection, likely due to Omicron (14, 15).

70

71 While several reports have examined post-vaccination Omicron infections, or Omicron
72 reinfections following exposure to prior variants (16-23), we are aware of only one study that
73 assessed repeat Omicron infection incidence through viral genomic surveillance (24). No studies
74 appear to have investigated the vaccine- and infection-induced immune responses after serial
75 Omicron infections. Here, we longitudinally characterize SARS-CoV-2 humoral responses in a
76 healthy young person who experienced serial BA.1 and BA.2 Omicron infections following

77 three-dose COVID-19 mRNA vaccination. Responses were compared to those of 124 COVID-
78 19-naive vaccinees over the same period. Taken together with existing literature, our results
79 suggest that vaccination provides limited protection against infection and/or reinfection by
80 Omicron variants.

81

82 **METHODS**

83

84 ***Observational COVID-19 vaccine cohort and SARS-CoV-2 infection monitoring.*** In December
85 2020, we established a prospective longitudinal study in Vancouver, Canada, to examine SARS-
86 CoV-2 specific humoral immune responses following vaccination with BNT162b2 (Comirnaty;
87 BioNTech/Pfizer) or mRNA-1273 (Spikevax; Moderna) in a cohort of 151 adults aged 24-98
88 years (described in (25, 26)). Serum and plasma were collected longitudinally up to 6 months
89 following the third dose (Figure 1A). At each visit, serum was tested for the presence of SARS-
90 CoV-2 anti-nucleocapsid (N) antibodies, which indicate seroconversion following infection,
91 using the Elecsys Anti-SARS-CoV-2 assay on a Cobas e601 module analyzer (Roche
92 Diagnostics). In addition to the case participant, immune measures from a comparison group of
93 124 additional cohort participants who remained anti-N seronegative up until at least one month
94 post-third vaccine dose are included for context.

95

96 ***Ethics approval.*** All participants provided written informed consent. This study was approved by
97 the University of British Columbia/Providence Health Care and Simon Fraser University
98 Research Ethics Boards (protocol H20-03906).

99

100 ***SARS-CoV-2 diagnostics and lineage confirmation.*** Diagnostic samples from the case
101 participant's two SARS-CoV-2 infections were tested at the St. Paul's Hospital Virology
102 Laboratory using the cobas® SARS-CoV-2 Test which targets conserved regions within the
103 Orf1a/b and E genes (Roche Diagnostics) followed by screening using a real-time reverse
104 transcription (RT)-PCR based algorithm for SARS-CoV-2 lineage classification that is
105 frequently updated to detect emerging variants (27, 28). Following this, the diagnostic samples
106 were subjected to full-genome SARS-CoV-2 sequencing in two independent laboratories: the BC
107 Centre for Disease Control, the provincial laboratory that performs all SARS-CoV-2 sequencing
108 for epidemiological surveillance, and the BC Centre for Excellence in HIV/AIDS. Both
109 laboratories use the Illumina platform. The SARS-CoV-2 full genome sequences for the
110 participant's BA.1.15 and subsequent BA.2 infections have been submitted to GISAID
111 (Accession ID EPI_ISL_12767799 and EPI_ISL_12662303, respectively).

112

113 ***Binding antibody assays.*** We quantified anti-Spike Receptor Binding Domain (RBD) binding
114 IgG concentrations in serum using the V-plex SARS-CoV-2 (IgG) Panel 22 ELISA kit (Meso
115 Scale Diagnostics), which features wild-type and Omicron BA.1 RBD antigens. For a subset of
116 participants, Anti-Spike binding IgG concentrations in serum were also quantified using the V-
117 plex SARS-CoV-2 (IgG) Panel 25 ELISA kit (Meso Scale Diagnostics), which features full-
118 length S antigens from wild-type, Omicron BA.1 and Omicron BA.2. At the time of analysis, no
119 panel featuring Omicron BA.2 RBD was offered by the manufacturer. Both assays were
120 performed on a Meso QuickPlex SQ120 instrument, with sera diluted 1:10000. Results are
121 reported in arbitrary Units/mL.

122

123 ***ACE2 competition assays.*** We assessed the ability of serum antibodies to block the wild-type
124 and Omicron BA.1 RBD-ACE2 receptor interaction by competition ELISA (Panel 22 V-plex
125 SARS-CoV-2 [ACE2]; Meso Scale Diagnostics). For a subset of participants, we also assessed
126 the ability of serum antibodies to block the wild-type, BA.1 and BA.2 Spike-ACE2 receptor
127 interaction using the same methods (Panel 25 V-plex SARS-CoV-2 [ACE2]). Both assays were
128 performed on a Meso QuickPlex SQ120 instrument, with sera diluted 1:40. Results are reported
129 as % ACE2 displacement.

130
131 ***Live virus neutralization assays.*** Neutralizing activity in plasma was examined in live SARS-
132 CoV-2 assays using a wild-type isolate (USA-WA1/2020; BEI Resources) and a local Omicron
133 BA.1 isolate (GISAID Accession # EPI_ISL_9805779) on VeroE6-TMPRSS2 (JCRB-1819)
134 target cells. Viral stock was adjusted to 50 TCID₅₀/200 µl in Dulbecco's Modified Eagle
135 Medium in the presence of serial 2-fold plasma dilutions (from 1/20 to 1/2560), incubated at 4°C
136 for 1 hour and added to target cells in 96-well plates in triplicate. Cultures were maintained at
137 37°C with 5% CO₂ and the appearance of viral cytopathic effect (CPE) was recorded three days
138 post-infection. Neutralizing activity is reported as the reciprocal of the highest plasma dilution
139 able to prevent CPE in all triplicate wells. Samples exhibiting partial or no neutralization at 1/20
140 dilution were defined as below the limit of quantification (BLOQ).

141
142 ***Statistical analysis.*** Data visualization and statistical analysis was conducted in Prism v9.2.0
143 (GraphPad).

144
145

146 **RESULTS**

147 *Case participant SARS-CoV-2 vaccination and infection timeline.*

148 The participant was a frontline health care worker in their early 30s with no chronic health
149 conditions. They received three doses of mRNA vaccine (all BNT162b2; 30mcg) in late
150 December 2020, early February 2021 and late October 2021 (Figure 1A). All blood samples
151 collected up to one month following the third immunization were anti-N seronegative.

152

153 In early January 2022, ten weeks after the third immunization, the participant experienced
154 moderate symptoms including sore throat, fatigue, congestion, body aches, severe headaches,
155 loss of taste and smell, coughing, shortness of breath and nausea. Symptoms, primarily cough,
156 intensified in the second week after diagnosis requiring corticosteroid therapy. By the third
157 week, symptoms had subsided except for shortness of breath and fatigue, with minimal
158 improvement from short- and long-acting bronchodilating agents. A saline gargle collected in
159 early January 2022 tested positive on the cobas® SARS-CoV-2 Test with a cycle threshold (Ct)
160 value of 21 for both Orf1a/b and E gene targets. Real-time RT-PCR-based molecular screening
161 identified the infection as Omicron BA.1, with subsequent full-genome viral sequencing
162 confirming the specific lineage as BA.1.15.

163

164 In early April 2022, 13 weeks following the BA.1 infection (and 23 weeks following the third
165 immunization) the participant experienced a different, more mild symptom profile compared to
166 their first infection, consisting of a sore throat, fever, body aches, headaches, and diarrhea. No
167 change in sense of taste or smell was noted. The participant noted persisting weakness, fatigue
168 and mental fog, as well as severe long-term, treatment-resistant shortness of breath triggered by

169 mild activities or exercises. A nasopharyngeal swab collected in early April 2022 tested positive
170 on the cobas® SARS-CoV-2 Test with Ct values of 24 (Orf1a/b) and 23 (E). This second
171 infection was identified as BA.2 by molecular screening and confirmed by full-genome viral
172 sequencing.

173

174 *Longitudinal humoral responses to wild-type and Omicron BA.1 variants*

175 We began by investigating the magnitude of the participant's humoral immune responses
176 following immunization, in context of a control group of 124 COVID-naïve individuals who
177 were vaccinated during the same period. The comparison group was 74% female with a median
178 age of 57 (Interquartile Range [IQR] 38-76) years. We quantified antibody responses to wild-
179 type and Omicron BA.1 strains in the participant and the comparison group at one month after
180 the second and third vaccine doses, as these time points should capture peak responses post-
181 vaccination (Figures 1B-D).

182

183 One month post-second dose, the participant's wild-type and BA.1-specific RBD IgG
184 concentrations were 4.90 and 4.26 log₁₀ U/mL respectively, which were equivalent to the 53rd
185 and 50th percentile values of the comparator cohort (Figure 1B). One month post-third dose, their
186 wild-type and BA.1-specific RBD IgG concentrations had increased to 5.08 and 4.63 log₁₀ U/mL
187 respectively, equivalent to the 36th and 60th percentile values of the cohort. Similarly, one month
188 post-second dose, their ability to disrupt the interaction between the ACE2 receptor and the wild-
189 type and BA.1 RBDs were 97% (57th percentile) and 42% (55th percentile) respectively (Figure
190 1C). At one month post-third dose, their wild-type- and BA.1-specific RBD-ACE2 displacement
191 activities had increased to 99% (74th percentile) and 76% (73rd percentile) respectively. Finally,

192 at one month post-second dose, the participant's plasma neutralized wild-type and BA.1 SARS-
193 CoV-2 at reciprocal dilutions of 320 and 20, which were equivalent to the 97th and 76th percentile
194 values of the cohort. At one month post-third dose, their wild-type and BA.1 neutralization titers
195 were 320 (78th percentile) and 40 (59th percentile) respectively. These results indicate that the
196 participant's overall vaccine responses were typical of the cohort, but nevertheless insufficient to
197 prevent infection by BA.1 approximately six weeks later.

198
199 Seventeen days after testing positive with BA.1 (which coincided with a three-month post-third-
200 dose study visit), the participant's wild-type and BA.1-specific responses were boosted
201 substantially, reaching the cohort 95th percentile for most measures at this time when immune
202 responses had begun to decline in the comparator cohort (Figures 1B-1D). Their wild-type RBD
203 IgG concentration increased to 5.71 log₁₀ U/mL, while their BA.1-specific RBD IgG
204 concentration increased to 5.11 log₁₀ U/mL (Figure 1B). For context, these values would have
205 placed the participant in the 95th and 93rd percentile of "peak" cohort values, measured at one
206 month post-third vaccine dose. Similarly, their wild-type-specific RBD-ACE2 competition
207 activity remained high at 99.9%, while their BA.1-specific RBD-ACE2 competition activity
208 increased to 96.3%. For context, these values were equivalent to the 99th percentiles of peak
209 cohort values one month after three vaccine doses (Figure 1C). Their wild-type and BA.1-
210 specific neutralization values held at 320 and 40, respectively, equivalent to the 78th and 59th
211 percentiles of peak cohort values (Figure 1D). These results indicate that BA.1 infection
212 substantially boosted the participant's humoral response, however this was insufficient to prevent
213 reinfection by BA.2 approximately 10 weeks later.

214

215 Sixteen days after testing positive with BA.2 (which coincided with a six-month post-third-dose
216 study visit), the participant's wild-type-specific responses remained steady or declined slightly
217 (e.g. RBD IgG) from prior measurements. Nevertheless, most values remained at the cohort
218 100th percentile at this time point, which is unsurprising given that vaccine-induced responses
219 had declined substantially over this time in the COVID-19 naive comparison group.

220
221 By contrast, the BA.2 reinfection had mixed effects on BA.1 responses. While the BA.1-specific
222 RBD IgG concentration rose substantially to 5.58 log₁₀ U/mL (whereas the cohort median at this
223 time point was nearly 2 log₁₀ lower), no change was seen for BA.1-specific RBD-ACE2
224 competition, and BA.1 neutralization increased only modestly. The more pronounced impact of
225 BA.2 reinfection was to extend the duration of BA.1-specific responses in the participant, who
226 maintained an RBD-ACE2 competition activity of 95.7% (cohort median 29% at this time point)
227 and a neutralization activity of 80 (cohort median BLOQ at this time point). Nevertheless,
228 despite BA.1 infection and BA.2 reinfection, the participant's virus neutralization activity against
229 BA.1 at this time point, which represented the highest activity measured during the study,
230 remained 4-fold lower compared to that against the wild-type strain one month following their
231 third vaccine dose (Figure 1D), suggesting that the participant may remain at risk of additional
232 Omicron infection.

233

234 ***Longitudinal humoral responses to Omicron BA.2***

235 We next characterized BA.2-specific Spike IgG and ACE2 competition activities in a subset of
236 participants (79% Female, median age 59 years) beginning one month following the third
237 vaccine dose (Figure 2). As these analyses focus on whole Spike (rather than RBD antigen), the

238 corresponding wild-type and BA.1-specific responses are also shown for context (Figure 2). We
239 additionally confirmed the (strong) correlations between wild-type- and BA.1-specific RBD and
240 Spike responses in these individuals (all $p < 0.0001$; Figure S1). At one month post-third vaccine
241 dose, the participant displayed wild-type, BA.1 and BA.2-specific Spike IgG concentrations of
242 5.81, 5.18 and 5.46 \log_{10} U/mL respectively (Figure 2A), and ACE2 competition activities of
243 99.4%, 50.6% and 64.3% respectively (Figure 2B). Their wild-type and BA.2-specific Spike IgG
244 concentrations were broadly average (54th and 68th percentiles respectively), as were their and
245 Spike-ACE2 competition activities (46th and 54th percentiles respectively), though their values
246 for BA.1-specific IgG and BA.1 Spike-ACE2 competition were slightly lower than average (37th
247 and 39th percentiles respectively).

248
249 Following BA.1 infection, the participant's wild-type, BA.1 and BA.2-specific Spike IgG
250 concentrations increased modestly, to 5.82, 5.22 and 5.48 \log_{10} U/mL respectively (Figure 2A).
251 Though the magnitude of these increases was not as pronounced as those observed for their wild-
252 type- and BA.1-specific RBD IgG concentrations (shown in Figure 1B), these values
253 nevertheless placed them at or above the cohort 85th percentile at this time point, when immune
254 responses had begun to decline in the broader cohort. For context, these values would place the
255 participant in the 57th, 39th, and 68th percentile of peak cohort values measured at one month
256 post-third vaccine dose. Similar to the ACE2 competition activities measured using RBD
257 antigens (shown in Figure 1C), the participant's wild-type Spike-ACE2 competition activities
258 remained high at 99.7%, while BA.1 and BA.2 Spike-ACE2 activities rose substantially to
259 87.9% and 89.3% respectively (Figure 2B); values that represented the 71st, 75th, and 79th
260 percentiles of peak cohort values at one month post-third vaccine dose.

261
262 Following BA.2 infection, the participant's wild-type Spike IgG concentration declined slightly
263 to 5.77 log₁₀ U/mL, whereas their BA.1 and BA.2-specific values increased slightly to 5.25 and
264 5.56 log₁₀ U/mL respectively (Figure 2A). These trends were consistent with their wild-type- and
265 BA.1-specific RBD IgG concentrations (shown in Figure 1B), though of a smaller magnitude.
266 Similar to the ACE2 competition activities measured using RBD antigens (shown in Figure 1C),
267 the participant's wild-type Spike-ACE2 competition activity remained high (99.5%) after BA.2
268 infection. BA.1 and BA.2 Spike-ACE2 activities increased, though only marginally, to 88.6%
269 and 90% respectively (Figure 2B).

270
271 Together, these results confirm that the participant's humoral responses to wild-type and
272 Omicron variants were broadly average one month post-third vaccine dose. Moreover, while
273 BA.1 infection boosted Omicron-specific immune responses (highlighted by an increase in BA.1
274 and BA.2 Spike-ACE2 competition activities), BA.2 reinfection did not substantially augment
275 these activities further but rather extended the duration of these responses.

276 **DISCUSSION**

278 This study provides detailed humoral characterization in a laboratory-confirmed case of serial
279 infection by SARS-CoV-2 Omicron subvariants BA.1 and BA.2 in an otherwise healthy adult
280 who had received three doses of COVID-19 mRNA vaccine. While data on repeat Omicron
281 infections remain very limited, a recent study from Denmark identified 47 cases of BA.2
282 reinfection that occurred between 20 and 60 days following BA.1 infection (24). The authors
283 concluded that such events were rare (<0.1% of cases during the brief window of analysis) and
284 more likely to occur among unvaccinated individuals, but further evaluation of the data indicates

285 a majority of reinfection cases were due to BA.2 following BA.1. Moreover, given that the
286 present case participant was one of only 151 enrollees of an observational COVID-19 vaccine
287 study (25, 26), our results suggest that the risk of serial infection with Omicron subvariants may
288 be greater than current assumptions based on low reinfection rates. We note however that the
289 participant's status as a frontline healthcare worker may have resulted in an increased risk of
290 exposure and (re-)infection over the general population.

291
292 Acknowledging that our ability to generalize from a single case is limited, we note that initial
293 vaccine-induced IgG, ACE2 competition and virus neutralization response magnitudes against
294 wild-type and Omicron BA.1 in the participant were comparable to the median values observed
295 in diverse controls who were vaccinated along the same timeline. The observation that average
296 humoral responses to three-dose vaccination failed to protect against Omicron BA.1 infection is
297 consistent with the extremely high rates of community transmission observed in many regions
298 during the recent Omicron-driven pandemic waves. Given that third doses substantially boost
299 humoral responses in individuals of all ages (29-32), the risk of Omicron infection is likely to be
300 higher among individuals who have received fewer than three doses (18, 33) and is likely to
301 increase with time following vaccination due to natural declines in antibody responses (26, 34-
302 37). Additional studies are needed to assess these factors.

303
304 While it is perhaps unsurprising that COVID-19 vaccines based on ancestral SARS-CoV-2
305 sequences will not generate sterilizing immunity against Omicron strains that have evolved to
306 evade host immune responses (4, 38-42), various lines of evidence suggest that "hybrid"
307 immunity resulting from vaccination plus infection provides greater protection against SARS-

308 CoV-2 variants (5, 43), due in part to maturation of Spike-specific antibodies (44-46) and
309 expansion of antiviral T cells (47-52). In light of this, we note that symptomatic BA.1 infection
310 boosted vaccine-induced humoral responses against both BA.1 and BA.2 in our case participant,
311 but the heightened response nevertheless failed to prevent subsequent symptomatic infection by
312 BA.2. Moreover, even after vaccination plus two Omicron infections, the participant's ACE2
313 competition and virus neutralization responses against BA.1 (as well as ACE2 competition
314 activity against BA.2) plateaued at levels substantially lower than those seen against the wild-
315 type strain, suggesting that the participant will remain at risk of new Omicron infections. A
316 limitation of our study is that it did not assess T cell responses, which can reduce disease severity
317 but may have less impact on virus transmission (53, 54), and thus we may be underestimating the
318 protection that results from infection and reinfection in this case. Indeed, the participant's
319 symptoms following both infections were not severe enough to require hospitalization,
320 demonstrating that vaccination was effective in its primary goal of preventing disease. Our
321 results nevertheless illustrate the potentially limited ability of current vaccines to prevent
322 recurrent infections and symptomatic disease caused by Omicron variants.

323

324 **DATA AVAILABILITY STATEMENT**

325 Sequences were submitted to GISAID. The raw data supporting the conclusions of this article
326 will be made available by the authors upon reasonable request.

327

328 **AUTHOR CONTRIBUTIONS**

329 HRL and FM contributed equally as first authors. MGR, MAB and ZLB obtained project funding
330 and contributed equally as senior authors. HRL, FM, MAB and ZLB designed the study. HRL,

331 FM, PKC, YS, FY, RK, SD, RW, GU, SE, LY, WD, DK, and LB contributed to specimen
332 collection and data analysis. HRL, YS, VL, DH, MLD, JS, NM, JSGM, CJB, NP, MN, CFL,
333 MGR, MAB, and ZLB supervised the research and contributed to project management. HRL,
334 MAB and ZLB wrote the original manuscript draft. All authors reviewed and approved the
335 submitted version of the manuscript.

336

337 **ACKNOWLEDGEMENTS**

338 We thank the leadership and staff of Providence Health Care for their support of this study. We
339 thank the phlebotomists and laboratory staff at St. Paul's Hospital, the BC Centre for Excellence
340 in HIV/AIDS, the Hope to Health Research and Innovation Centre, and Simon Fraser University
341 for assistance. Above all, we thank the participants, without whom this study would not have
342 been possible.

343

344 **FUNDING**

345

346 This work was supported by the Public Health Agency of Canada through a COVID-19
347 Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120 to MGR, ZLB,
348 MAB). Additional funding was received from the Canadian Institutes for Health Research (GA2-
349 177713 and the Coronavirus Variants Rapid Response Network (FRN-175622) to MAB) and the
350 Canada Foundation for Innovation through Exceptional Opportunities Fund - COVID-19 awards
351 (to MAB, MD, MN, RP, CFL, ZLB). MLD and ZLB hold Scholar Awards from the Michael
352 Smith Foundation for Health Research. FY was supported by an SFU Undergraduate Student
353 Research Award. GU holds a Ph.D. fellowship from the Sub-Saharan African Network for
354 TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [grant # DEL-15-006].
355 The DELTAS Africa Initiative is an independent funding scheme of the African Academy of

356 Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESAs) and
357 supported by the New Partnership for Africa's Development Planning and Coordinating Agency
358 (NEPAD Agency) with funding from the Wellcome Trust [grant # 107752/Z/15/Z] and the UK
359 government. The views expressed in this publication are those of the authors and not necessarily
360 those of AAS, NEPAD Agency, Wellcome Trust or the UK government.

361

362 **CONFLICT OF INTEREST**

363 The authors declare that the research was conducted in the absence of any commercial or
364 financial relationships that could be construed as a potential conflict of interest.

365

366 **FIGURE LEGENDS**

367

368 **Figure 1. Case participant history and longitudinal humoral responses against wild-type**
369 **and Omicron BA.1 SARS-CoV-2.** Panel A: Case participant timeline. Immunizations and
370 SARS-CoV-2 Omicron infection history are shown at the top. Longitudinal SARS-CoV-2 anti-N
371 serology results are shown in small green (anti-N negative) or orange (anti-N positive) circles.
372 Large black circles denote time points where additional humoral functions, shown in panels
373 below, were measured. Panel B: Longitudinal anti-S-RBD IgG log₁₀ concentrations in case
374 participant (large circles) versus the comparison group of SARS-CoV-2-naive individuals (small
375 circles) at various time points following two- and three-dose COVID-19 vaccination. Wild-type
376 (WT) specific anti-S-RBD responses are shown in red; Omicron BA.1-specific ones are shown in
377 blue. Matching solid lines connect the participant's longitudinal values, while dotted lines
378 connect the median values for the comparison group. Approximate times of BA.1 and BA.2
379 infections are shown with arrows. Total Ns (including the case participant) are shown at the
380 bottom of the plot. Later time points have smaller Ns because some control participants were
381 censored due to post-vaccination SARS-CoV-2 infection or had not yet completed the visit.
382 Panel C: same as previous, but for longitudinal ACE2% displacement function from wild-type
383 (red) and BA.1 (blue) S-RBDs. Panel D: same as previous, but for longitudinal live virus
384 neutralization function against wild-type (red) and BA.1 (blue) strains. ULOQ/LLOQ:
385 upper/lower limit of quantification.

386

387 **Figure 2. Longitudinal humoral responses against wild-type, BA.1 and BA.2 Spike**
388 **antigens.** Panel A: Anti-Spike IgG log₁₀ concentrations in case participant (large circles) versus
389 the subset of the comparison group of SARS-CoV-2-naive individuals (small circles) at one,
390 three and six months following three-dose COVID-19 vaccination. Wild-type-specific (WT)
391 anti-Spike responses are in red; BA.1-specific ones are in blue; BA.2-specific ones are in black.
392 Matching solid lines connect the participant's longitudinal values; dotted lines connect the
393 median values for the comparison group. Approximate times of BA.1 and BA.2 infections are
394 shown with arrows. Total Ns (including the case participant) are shown at the bottom of the plot;
395 the final time point has a smaller N because some control participants were censored due to post-
396 vaccination SARS-CoV-2 infection or had not yet completed the visit. Panel B: same as
397 previous, but for longitudinal ACE2% displacement function from wild-type (red), BA.1 (blue)
398 and BA.2 (black) Spike protein.

399

400 **Figure S1. Correlations between wild-type (WT) and BA.1-specific anti-S-RBD and anti-**
401 **Spike humoral responses measured following three COVID-19 vaccine doses using Meso**
402 **Scale Diagnostics V-plex panels 22 and 25.** All participants who were evaluated for BA.2
403 responses (i.e. those shown in Figure 2) are included in this analysis. Symbols are coloured
404 based on post-vaccination time point, though the Spearman's rho (ρ) and p-value reported are for
405 the combined data.

406

407 **REFERENCES**

- 408
- 409 1. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al.
410 Increased Risk of Sars-Cov-2 Reinfection Associated with Emergence of Omicron in South
411 Africa. *Science* (2022) 376(6593):eabn4947. Epub 20220506. doi:
412 10.1126/science.abn4947.
- 413 2. Bastard J, Taisne B, Figoni J, Mailles A, Durand J, Fayad M, et al. Impact of the Omicron
414 Variant on Sars-Cov-2 Reinfections in France, March 2021 to February 2022. *Euro*
415 *Surveill* (2022) 27(13). doi: 10.2807/1560-7917.ES.2022.27.13.2200247.
- 416 3. Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, et al.
417 Protection against the Omicron Variant from Previous Sars-Cov-2 Infection. *N Engl J Med*
418 (2022) 386(13):1288-90. Epub 20220209. doi: 10.1056/NEJMc2200133.
- 419 4. Cele S, Jackson L, Houry DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron
420 Extensively but Incompletely Escapes Pfizer Bnt162b2 Neutralization. *Nature* (2022)
421 602(7898):654-6. Epub 20211223. doi: 10.1038/s41586-021-04387-1.
- 422 5. Smid M, Berec L, Pribylova L, Majek O, Pavlik T, Jarkovsky J, et al. Protection by
423 Vaccines and Previous Infection against the Omicron Variant of Sars-Cov-2. *J Infect Dis*
424 (2022). Epub 20220428. doi: 10.1093/infdis/jiac161.
- 425 6. Ahava MJ, Jarva H, Jaaskelainen AJ, Lappalainen M, Vapalahti O, Kurkela S. Rapid
426 Increase in Sars-Cov-2 Seroprevalence During the Emergence of Omicron Variant,
427 Finland. *Eur J Clin Microbiol Infect Dis* (2022). Epub 20220428. doi: 10.1007/s10096-
428 022-04448-x.
- 429 7. Chaguza C, Coppi A, Earnest R, Ferguson D, Kerantzas N, Warner F, et al. Rapid
430 Emergence of Sars-Cov-2 Omicron Variant Is Associated with an Infection Advantage
431 over Delta in Vaccinated Persons. *Med (N Y)* (2022). Epub 20220406. doi:
432 10.1016/j.medj.2022.03.010.
- 433 8. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid
434 Epidemic Expansion of the Sars-Cov-2 Omicron Variant in Southern Africa. *Nature* (2022)
435 603(7902):679-86. Epub 20220107. doi: 10.1038/s41586-022-04411-y.
- 436 9. Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al. Omicron Sub-Lineages
437 Ba.4/Ba.5 Escape Ba.1 Infection Elicited Neutralizing Immunity. *medRxiv*
438 (2022):2022.04.29.22274477. doi: 10.1101/2022.04.29.22274477.
- 439 10. BC Centre for Disease Control. Weekly Update on Variants of Concern - 05 May (2022).
440 Available from: <http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data>.
- 441 11. BC Centre for Disease Control. Weekly Reporting of Covid-19 Cases, Hospitalizations,
442 and Deaths - 05 May (2022). Available from: [http://www.bccdc.ca/health-info/diseases-](http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data)
443 [conditions/covid-19/data](http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data).

- 444 12. Public Health Agency of Canada. Canadian Covid-19 Vaccination Coverage Report -29
445 April (2022). Available from: [https://health-infobase.canada.ca/covid-19/vaccination-
446 coverage/](https://health-infobase.canada.ca/covid-19/vaccination-coverage/).
- 447 13. Government of British Columbia. Get a Booster Dose - Province of British Columbia
448 (2022). Available from: <https://www2.gov.bc.ca/gov/content/covid-19/vaccine/booster>.
- 449 14. Steacy L. B.C. Covid News: Omicron Infected Half of British Columbians, Henry Says
450 Vancouver, Canada(2022) [updated 5 April 2022]. Available from:
451 [https://bc.ctvnews.ca/omicron-wave-exposed-infected-50-per-cent-of-british-columbians-
452 henry-1.5850076](https://bc.ctvnews.ca/omicron-wave-exposed-infected-50-per-cent-of-british-columbians-henry-1.5850076).
- 453 15. Miller A. Almost Half of Canadians May Have Caught Covid: CBC News (2022) [updated
454 23 April 2022]. Available from: [https://www.cbc.ca/news/health/omicron-immunity-
455 canada-covid19-vaccines-1.6428536](https://www.cbc.ca/news/health/omicron-immunity-canada-covid19-vaccines-1.6428536).
- 456 16. Paterson S. B.C. Doctors Seeing Covid-19 Reinfection in Patients Who Recently Had
457 Omicron Vancouver, Canada(2022) [updated 2 April 2022]. Available from:
458 [https://bc.ctvnews.ca/b-c-doctors-seeing-covid-19-reinfection-in-patients-who-recently-
459 had-omicron-1.5846079](https://bc.ctvnews.ca/b-c-doctors-seeing-covid-19-reinfection-in-patients-who-recently-had-omicron-1.5846079).
- 460 17. Chang MR, Ke H, Coherd CD, Wang Y, Mashima K, Kastrunes GM, et al. Analysis of a
461 Sars-Cov-2 Convalescent Cohort Identified a Common Strategy for Escape of Vaccine-
462 Induced Anti-Rbd Antibodies by Beta and Omicron Variants. *EBioMedicine* (2022)
463 80:104025. Epub 20220506. doi: 10.1016/j.ebiom.2022.104025.
- 464 18. Curlin ME, Bates TA, Guzman G, Schoen D, McBride SK, Carpenter SD, et al. Omicron
465 Neutralizing Antibody Response Following Booster Vaccination Compared with
466 Breakthrough Infection. *medRxiv* (2022). Epub 20220412. doi:
467 10.1101/2022.04.11.22273694.
- 468 19. Servellita V, Syed AM, Morris MK, Brazer N, Saldhi P, Garcia-Knight M, et al.
469 Neutralizing Immunity in Vaccine Breakthrough Infections from the Sars-Cov-2 Omicron
470 and Delta Variants. *Cell* (2022) 185(9):1539-48 e5. Epub 20220318. doi:
471 10.1016/j.cell.2022.03.019.
- 472 20. Glatman-Freedman A, Bromberg M, Hershkovitz Y, Sefty H, Kaufman Z, Dichtiar R, et al.
473 Effectiveness of Bnt162b2 Vaccine Booster against Sars-Cov-2 Infection and
474 Breakthrough Complications, Israel. *Emerg Infect Dis* (2022) 28(5):948-56. Epub
475 20220401. doi: 10.3201/eid2805.220141.
- 476 21. Seaman MS, Siedner MJ, Boucau J, Lavine CL, Ghantous F, Liew MY, et al. Vaccine
477 Breakthrough Infection with the Sars-Cov-2 Delta or Omicron (Ba.1) Variant Leads to
478 Distinct Profiles of Neutralizing Antibody Responses. *medRxiv* (2022). Epub 20220303.
479 doi: 10.1101/2022.03.02.22271731.
- 480 22. Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, et al. Neutralizing Antibody
481 Responses Elicited by Sars-Cov-2 Mrna Vaccination Wane over Time and Are Boosted by

- 482 Breakthrough Infection. *Sci Transl Med* (2022) 14(637):eabn8057. Epub 20220323. doi:
483 10.1126/scitranslmed.abn8057.
- 484 23. Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, et al.
485 Breakthrough Infections with Sars-Cov-2 Omicron Despite Mrna Vaccine Booster Dose.
486 *Lancet* (2022) 399(10325):625-6. Epub 20220118. doi: 10.1016/S0140-6736(22)00090-3.
- 487 24. Stegger M, Edslev SM, Sieber RN, Cäcilia Ingham A, Ng KL, Tang M-HE, et al.
488 Occurrence and Significance of Omicron Ba.1 Infection Followed by Ba.2 Reinfection.
489 *medRxiv* (2022):2022.02.19.22271112. doi: 10.1101/2022.02.19.22271112.
- 490 25. Brockman MA, Mwimanzi F, Lapointe HR, Sang Y, Agafitei O, Cheung P, et al. Reduced
491 Magnitude and Durability of Humoral Immune Responses to Covid-19 Mrna Vaccines
492 among Older Adults. *J Infect Dis* (2021) Online ahead of print. Accepted 9 Dec 2021. doi:
493 10.1093/infdis/jiab592. Epub 20211209. doi: 10.1093/infdis/jiab592.
- 494 26. Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umvilighozo G, et al. Older
495 Adults Mount Less Durable Humoral Responses to Two Doses of Covid-19 Mrna Vaccine,
496 but Strong Initial Responses to a Third Dose. *J Infect Dis* (2022). Epub 20220511. doi:
497 10.1093/infdis/jiac199.
- 498 27. Matic N, Lowe CF, Ritchie G, Stefanovic A, Lawson T, Jang W, et al. Rapid Detection of
499 Sars-Cov-2 Variants of Concern, Including B.1.1.28/P.1, British Columbia, Canada. *Emerg*
500 *Infect Dis* (2021) 27(6):1673-6. Epub 20210330. doi: 10.3201/eid2706.210532.
- 501 28. Matic N, Lowe CF, Ritchie G, Young M, Lawson T, Romney MG. Omicron (B.1.1.529)
502 Sars-Cov-2 Viral Load among Nasopharyngeal and Oral Samples Compared to Other
503 Variants of Concern and Impact on Diagnostic Testing Strategy. *Clin Microbiol Infect*
504 (2022). Epub 2022/05/15. doi: 10.1016/j.cmi.2022.04.022.
- 505 29. Lustig Y, Gonen T, Meltzer L, Gilboa M, Indenbaum V, Cohen C, et al. Superior
506 Immunogenicity and Effectiveness of the Third Compared to the Second Bnt162b2
507 Vaccine Dose. *Nat Immunol* (2022). Epub 20220509. doi: 10.1038/s41590-022-01212-3.
- 508 30. Liu X, Munro APS, Feng S, Janani L, Aley PK, Babbage G, et al. Persistence of
509 Immunogenicity after Seven Covid-19 Vaccines Given as Third Dose Boosters Following
510 Two Doses of Chadox1 Ncov-19 or Bnt162b2 in the Uk: Three Month Analyses of the
511 Cov-Boost Trial. *J Infect* (2022). Epub 20220409. doi: 10.1016/j.jinf.2022.04.018.
- 512 31. Moreira ED, Jr., Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety and
513 Efficacy of a Third Dose of Bnt162b2 Covid-19 Vaccine. *N Engl J Med* (2022). Epub
514 20220323. doi: 10.1056/NEJMoa2200674.
- 515 32. Yoon SK, Hegmann KT, Thiese MS, Burgess JL, Ellingson K, Lutrick K, et al. Protection
516 with a Third Dose of Mrna Vaccine against Sars-Cov-2 Variants in Frontline Workers. *N*
517 *Engl J Med* (2022) 386(19):1855-7. Epub 20220406. doi: 10.1056/NEJMc2201821.


- 518 33. Goel RR, Painter MM, Lundgreen KA, Apostolidis SA, Baxter AE, Giles JR, et al.
519 Efficient Recall of Omicron-Reactive B Cell Memory after a Third Dose of Sars-Cov-2
520 Mrna Vaccine. *Cell* (2022). Epub 20220408. doi: 10.1016/j.cell.2022.04.009.
- 521 34. Mantus G, Nyhoff LE, Edara VV, Zarnitsyna VI, Ciric CR, Flowers MW, et al. Pre-
522 Existing Sars-Cov-2 Immunity Influences Potency, Breadth, and Durability of the Humoral
523 Response to Sars-Cov-2 Vaccination. *Cell Rep Med* (2022) 3(4):100603. Epub 20220329.
524 doi: 10.1016/j.xcrm.2022.100603.
- 525 35. Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, et al. Durability of
526 Bnt162b2 Vaccine against Hospital and Emergency Department Admissions Due to the
527 Omicron and Delta Variants in a Large Health System in the USA: A Test-Negative Case-
528 Control Study. *Lancet Respir Med* (2022). Epub 20220422. doi: 10.1016/S2213-
529 2600(22)00101-1.
- 530 36. Bonnet B, Chabrolles H, Archimbaud C, Brebion A, Cosme J, Dutheil F, et al. Decline of
531 Humoral and Cellular Immune Responses against Sars-Cov-2 6 Months after Full
532 Bnt162b2 Vaccination in Hospital Healthcare Workers. *Front Immunol* (2022) 13:842912.
533 Epub 20220302. doi: 10.3389/fimmu.2022.842912.
- 534 37. Sogaard OS, Reekie J, Johansen IS, Nielsen H, Benfield T, Wiese L, et al. Characteristics
535 Associated with Serological Covid-19 Vaccine Response and Durability in an Older
536 Population with Significant Comorbidity: The Danish Nationwide Enforce Study. *Clin
537 Microbiol Infect* (2022). Epub 20220311. doi: 10.1016/j.cmi.2022.03.003.
- 538 38. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19
539 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *New England Journal of
540 Medicine* (2022) 386(16):1532-46. doi: 10.1056/NEJMoa2119451.
- 541 39. Bjork J, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al.
542 Covid-19 Vaccine Effectiveness against Severe Disease from Sars-Cov-2 Omicron Ba.1
543 and Ba.2 Subvariants - Surveillance Results from Southern Sweden, December 2021 to
544 March 2022. *Euro Surveill* (2022) 27(18). doi: 10.2807/1560-
545 7917.ES.2022.27.18.2200322.
- 546 40. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of Bnt162b2
547 Vaccine against Omicron Variant in South Africa. *N Engl J Med* (2022) 386(5):494-6.
548 Epub 20211229. doi: 10.1056/NEJMc2119270.
- 549 41. Yu J, Collier AY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of the
550 Sars-Cov-2 Omicron Ba.1 and Ba.2 Variants. *N Engl J Med* (2022) 386(16):1579-80. Epub
551 20220316. doi: 10.1056/NEJMc2201849.
- 552 42. Pedersen RM, Bang LL, Madsen LW, Sydenham TV, Johansen IS, Jensen TG, et al. Serum
553 Neutralization of Sars-Cov-2 Omicron Ba.1 and Ba.2 after Bnt162b2 Booster Vaccination.
554 *Emerg Infect Dis* (2022) 28(6). Epub 20220331. doi: 10.3201/eid2806.220503.

- 555 43. Nordstrom P, Ballin M, Nordstrom A. Risk of Sars-Cov-2 Reinfection and Covid-19
556 Hospitalisation in Individuals with Natural and Hybrid Immunity: A Retrospective, Total
557 Population Cohort Study in Sweden. *Lancet Infect Dis* (2022). Epub 20220331. doi:
558 10.1016/S1473-3099(22)00143-8.
- 559 44. Chen Y, Tong P, Whiteman N, Moghaddam AS, Zarghami M, Zuiani A, et al. Immune
560 Recall Improves Antibody Durability and Breadth to Sars-Cov-2 Variants. *Sci Immunol*
561 (2022):eabp8328. Epub 2022/05/14. doi: 10.1126/sciimmunol.abp8328.
- 562 45. Cho A, Muecksch F, Schaefer-Babajew D, Wang Z, Finkin S, Gaebler C, et al. Anti-Sars-
563 Cov-2 Receptor-Binding Domain Antibody Evolution after Mrna Vaccination. *Nature*
564 (2021) 600(7889):517-22. Epub 20211007. doi: 10.1038/s41586-021-04060-7.
- 565 46. Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, et al.
566 Affinity Maturation of Sars-Cov-2 Neutralizing Antibodies Confers Potency, Breadth, and
567 Resilience to Viral Escape Mutations. *Immunity* (2021) 54(8):1853-68 e7. Epub 20210730.
568 doi: 10.1016/j.immuni.2021.07.008.
- 569 47. Rodda LB, Morawski PA, Pruner KB, Fahning ML, Howard CA, Franko N, et al.
570 Imprinted Sars-Cov-2-Specific Memory Lymphocytes Define Hybrid Immunity. *Cell*
571 (2022) 185(9):1588-601 e14. Epub 20220317. doi: 10.1016/j.cell.2022.03.018.
- 572 48. Riou C, Keeton R, Moyo-Gwete T, Hermanus T, Kgagudi P, Baguma R, et al. Escape from
573 Recognition of Sars-Cov-2 Variant Spike Epitopes but Overall Preservation of T Cell
574 Immunity. *Sci Transl Med* (2022) 14(631):eabj6824. Epub 20220209. doi:
575 10.1126/scitranslmed.abj6824.
- 576 49. Keeton R, Richardson SI, Moyo-Gwete T, Hermanus T, Tincho MB, Benede N, et al. Prior
577 Infection with Sars-Cov-2 Boosts and Broadens Ad26.Cov2.S Immunogenicity in a
578 Variant-Dependent Manner. *Cell Host Microbe* (2021) 29(11):1611-9 e5. Epub 20211013.
579 doi: 10.1016/j.chom.2021.10.003.
- 580 50. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al. T Cell Responses
581 to Sars-Cov-2 Spike Cross-Recognize Omicron. *Nature* (2022) 603(7901):488-92. Epub
582 20220131. doi: 10.1038/s41586-022-04460-3.
- 583 51. Gao Y, Cai C, Grifoni A, Muller TR, Niessl J, Olofsson A, et al. Ancestral Sars-Cov-2-
584 Specific T Cells Cross-Recognize the Omicron Variant. *Nat Med* (2022) 28(3):472-6. Epub
585 20220114. doi: 10.1038/s41591-022-01700-x.
- 586 52. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. Mrna
587 Vaccines Induce Durable Immune Memory to Sars-Cov-2 and Variants of Concern.
588 *Science* (2021) 374(6572):abm0829. Epub 20211203. doi: 10.1126/science.abm0829.
- 589 53. Pollard AJ, Bijker EM. A Guide to Vaccinology: From Basic Principles to New
590 Developments. *Nat Rev Immunol* (2021) 21(2):83-100. Epub 20201222. doi:
591 10.1038/s41577-020-00479-7.


- 592 54. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological
593 Considerations for Covid-19 Vaccine Strategies. *Nat Rev Immunol* (2020) 20(10):615-32.
594 Epub 20200904. doi: 10.1038/s41577-020-00434-6.
595

596


A




B




C



D




A




- responses against WT (ancestral)
- responses against Omicron BA.1
- responses against Omicron BA.2

B




- reinfection case
- median SARS-CoV-2-naive controls


A



B



C



D

